EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization

Biykem Bozkurt, Gianluigi Savarese, Samuel Adamsson Eryd, Johan Bodegård, John G F Cleland, Cindy Khordoc, Takuya Kishi, Marcus Thuresson, Orly Vardeny, Ruiqi Zhang, Lars H Lund

JACC: Heart Failure · 2023-10 · 11 (10) · 1320-1332

DOI: 10.1016/j.jchf.2023.04.017 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JACC: Heart Failure, 2023-10. Verfasst von Biykem Bozkurt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Winters Center for Heart Failure, Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, AstraZeneca Mölndal, AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are few contemporary data on outcomes, costs, and treatment following a hospitalization for heart failure (hHF) in epidemiologically representative cohorts. OBJECTIVES: This study sought to describe rehospitalizations, hospitalization costs, use of guideline-directed medical therapy (GDMT) (renin-angiotensin system inhibitors, sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors), and mortality after hHF. METHODS: EVOLUTION HF (Utilization of Dapagliflozin and Other Guideline Directed Medical Therapies in Heart Failure Patients: A Multinational Observational Study Based on Secondary Data) is an observational, longitudinal cohort study using data from electronic health records or claims data sources in Japan, Sweden, the United Kingdom, and the United States. Adults with a first hHF discharge between 2018 and 2022 were included. The 1-year event rates per 100 patient-years (ERs) for death and rehospitalizations (with a primary diagnosis of heart failure (HF), chronic kidney disease [CKD], myocardial infarction, stroke, or peripheral artery disease) were calculated. Hospital health care costs were cumulatively summarized. Cumulative GDMT use was assessed using Kaplan-Meier estimates. RESULTS: Of 263,525 patients, 28% died within the first year post-hHF (ER: 28.4 [95% CI: 27.0-29.9]). Rehospitalizations were mainly driven by HF (ER: 13.6 [95% CI: 9.8-17.4]) and CKD (ER: 4.5 [95% CI: 3.6-5.3]), whereas the ERs for myocardial infarction, stroke, and peripheral artery disease were lower. Health care costs were predominantly driven by HF and CKD. Between 2020 and 2022, use of renin-angiotensin system inhibitors, sacubitril/valsartan, beta-blockers, and mineralocorticoid receptor antagonists changed little, whereas uptake of sodium-glucose cotransporter-2 inhibitors increased 2- to 7-fold. CONCLUSIONS: Incident post-hHF rehospitalization risks and costs were high, and GDMT use changed little in the year following discharge, highlighting the need to consider earlier and greater implementation of GDMT to manage risks and reduce costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSodium-Glucose Transporter 2 InhibitorsMyocardial InfarctionStrokeRenal Insufficiency, ChronicPeripheral Arterial DiseaseAdultHumansUnited StatesLongitudinal StudiesMineralocorticoid Receptor AntagonistsValsartanAntihypertensive AgentsHospitalizationAdrenergic beta-AntagonistsStroke VolumeAngiotensin Receptor AntagonistsGlucoseSodiumAminobutyratesBiphenyl Compounds

Stichwörter der Autor:innen

guideline-directed medical therapyguideline-recommended pharmacotherapyhealth care costhospitalization for heart failureincident heart failuremortality

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsValsartanAntihypertensive AgentsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsGlucoseSodiumsacubitrilAminobutyrates

Autor:innen und Institutionen

  • Winters Center for Heart Failure, Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA.
  • Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. Electronic address: gianluigi.savarese@ki.se.
  • CVRM Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware, USA.
  • Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare, Okawa, Japan.

Förderung

  • British Heart Foundation
  • AstraZeneca Mölndal
  • AstraZeneca PLC

Zitieren

APA

Bozkurt, B., Savarese, G., Adamsson Eryd, S., Bodegård, J., Cleland, J. G. F., Khordoc, C., Kishi, T., Thuresson, M., Vardeny, O., Zhang, R., & Lund, L. H. (2023). Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization. JACC: Heart Failure, 11(10), 1320-1332. https://doi.org/10.1016/j.jchf.2023.04.017

Vancouver

Bozkurt B, Savarese G, Adamsson Eryd S, Bodegård J, Cleland JGF, Khordoc C, et al. Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization. JACC: Heart Failure. 2023;11(10):1320-1332. doi:10.1016/j.jchf.2023.04.017

BibTeX
@article{Bozkurt2023,
  author = {Bozkurt, Biykem and Savarese, Gianluigi and Adamsson Eryd, Samuel and Bodegård, Johan and Cleland, John G F and Khordoc, Cindy and Kishi, Takuya and Thuresson, Marcus and Vardeny, Orly and Zhang, Ruiqi and Lund, Lars H},
  title = {Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization},
  journal = {JACC: Heart Failure},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {1320--1332},
  doi = {10.1016/j.jchf.2023.04.017}
}
Kostenlos starten →